0001104659-21-110763.txt : 20210830
0001104659-21-110763.hdr.sgml : 20210830
20210830090855
ACCESSION NUMBER: 0001104659-21-110763
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210827
FILED AS OF DATE: 20210830
DATE AS OF CHANGE: 20210830
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Elanco Animal Health Inc
CENTRAL INDEX KEY: 0001739104
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36225
FILM NUMBER: 211221235
BUSINESS ADDRESS:
STREET 1: 2500 INNOVATION WAY
CITY: GREENFIELD
STATE: IN
ZIP: 46140
BUSINESS PHONE: 877-352-6261
MAIL ADDRESS:
STREET 1: 2500 INNOVATION WAY
CITY: GREENFIELD
STATE: IN
ZIP: 46140
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kindred Biosciences, Inc.
CENTRAL INDEX KEY: 0001561743
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 461160142
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1555 BAYSHORE HIGHWAY, SUITE 200
CITY: BURLINGAME
STATE: CA
ZIP: 94010
BUSINESS PHONE: 650-701-7901
MAIL ADDRESS:
STREET 1: 1555 BAYSHORE HIGHWAY, SUITE 200
CITY: BURLINGAME
STATE: CA
ZIP: 94010
4
1
tm2126057-1_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-08-27
1
0001561743
Kindred Biosciences, Inc.
KIN
0001739104
Elanco Animal Health Inc
2500 INNOVATION WAY
GREENFIELD
IN
46140
0
0
1
0
Common Stock, par value $0.0001
2021-08-27
4
P
0
45508938
9.25
A
10000
D
Pursuant to the Agreement and Plan of Merger, dated as of June 15, 2021 and as amended on June 30, 2021, by and among Elanco Animal Health Incorporated, Knight Merger Sub, Inc., a wholly owned subsidiary of Elanco Animal Health Incorporated ("Merger Sub"), and Kindred Biosciences, Inc. ("KindredBio"), Merger Sub merged with and into KindredBio (the "Merger") on August 27, 2021. Upon completion of the Merger, each share of common stock of KindredBio that was issued and outstanding immediately prior to the effective time of the Merger was cancelled, and each share of common stock of Merger Sub was converted into one share of common stock of the surviving corporation. Consequently, upon the consummation of the Merger on August 27, 2021, Elanco became the owner of 10,000 shares of common stock of the surviving corporation, representing 100% of the issued and outstanding shares of common stock of the surviving corporation.
/s/ Todd Young Todd Young as Executive Vice President and Chief Financial Officer of Elanco Animal Health Incorporated
2021-08-30